Table 5. SUCRA-Based Primary Efficacy and Safety Outcome Rankings from Hypertensive RCTs.
| Primary safety outcome rankings | ||||
|---|---|---|---|---|
| Intervention | Primary efficacy | Dry cough | Presyncope | Peripheral edema |
| outcome ranking* | ranking* | ranking* | ranking* | |
| ACEI | - | - | 1 | 4 |
| ACEI+amlodipine | - | - | - | - |
| Amlodipine | 3 | 1 | - | - |
| Amlodipine+fosinopril | 1 | 2 | - | - |
| Benazepril | - | - | - | - |
| Benazepril+amlodipine | - | - | - | - |
| Candesartan | - | - | 4 | 5 |
| Candesartan+HCTZ | - | - | - | - |
| Candesartan+lisinopril | - | - | 3 | 2 |
| Candesartan+manidipine | - | - | - | - |
| Captopril+diltiazem | - | - | - | - |
| Enalapril | 5 | 4 | - | - |
| Fosinopril | 2 | 3 | - | - |
| Lisinopril | 4 | - | 5 | 3 |
| Lisinopril+telmisartan† | 6 | - | - | - |
| Losartan+HCTZ | - | - | - | - |
| Manidipine | 8 | - | - | 6 |
| Manidipine+delapril | - | - | - | - |
| Nitrendipine | 10 | - | - | - |
| Perindopril | - | - | - | - |
| Perindopril+indapamide | - | - | - | - |
| Telmisartan | 9 | - | - | - |
| Telmisartan+lisinopril† | - | - | - | - |
| Telmisartan+TCMZ | - | - | - | - |
| Telmisartan+TCMZ+amlodipine | - | - | - | - |
| Valsartan+amlodipine+canrenone | - | - | - | - |
| Valsartan+amlodipine+HCTZ | - | - | - | - |
*Placebo was ranked 7th in the primary efficacy outcome, was not ranked in the cough safety outcome, was ranked 2nd in the presyncope safety outcome, and was ranked 1st in the peripheral edema safety outcome.
†Lisinopril+telmisartan refers to lisinopril+telmisartan combination therapy following lisinopril monotherapy, while telmisartan+lisinopril refers to lisinopril+telmisartan combination therapy following telmisartan monotherapy.